Exclusivity would drive the licensing fee up and likely get the 510K and any associated capital costs covered by Platinum rather than DECN.
It's a win-win for both sides, assuming there is any validity to it.
(0)
(0)
Decision Diagnostics Corp (DECN) Stock Research Links
-
-
-
-
-
-
-